Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Country Delight, a trusted name in premium and natural essentials, has announced the launch of 100% Pure Farm Honey (NMR ...

A serious addiction was sending Michelle Oberg to an early grave. But it wasn’t an addiction to drugs or alcohol. Even though ...

Morgan Stanley raised the firm’s price target on Sana Biotechnology (SANA) to $12 from $9 and keeps an Overweight rating on the shares. Based ...

As part of our Masterclass series, GP specialist in diabetes Dr Elizabeth Martin explains the key points in prevention, diagnosis and management of diabetes in general practice. This series showcases ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

The results were supported by the presence of circulating C-peptide, a biomarker indicating insulin production by the transplanted beta cells. C-peptide levels further increased during a mixed ...

The interim results from their UP421 therapy in Type 1 Diabetes (T1D) demonstrated no adverse effects, along with detectable C-peptide levels and evidence of immune evasion, indicating a strong proof ...

Diamyd Medical has released an updated analysis of the commercial potential for its lead product candidate, the precision immunotherapy Diamyd® (rhGAD65/alum) in the U.S. market. The addressable ...

Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.